Psilox
Reference number | |
Coordinator | BIOMATCELL AB |
Funding from Vinnova | SEK 2 000 000 |
Project duration | May 2013 - December 2014 |
Status | Completed |
Important results from the project
The project aimed to develop a business plan, regulatory strategy, manufacturing strategy, protect technology with IPR and prove the mode-of-action in the clinic. The goal was to create a base for future commercialization. These aspects have been investigated during the project and all of them except one clinical study has been carried out. For the future, the technology has now been placed in a company and a first new emission of shares has been filled and will be completed shortly.
Expected long term effects
The outcome for the project is that a new company has been created with the basis from the documents and information gained under VinnVeriferingsprojektet. The company has now secured a first investment and will be able to start implementing the business plan.
Approach and implementation
The set-up to work toward milestones have been good for the project when the focus of each part has guided project for business development, process development and proof of the technology in key tests.